Comparison of the effect of normal flushing of heparinized saline with subcutaneous injection of enoxaparin with a prophylactic dose in preventing central venous catheter thrombosis

Comparison of the effect of heparinized normal saline flushing with prophylactic dose enoxaparin subcutaneous injection in the prevention of central venous catheter thrombosis in hospitalized high-risk patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230428058015N1

Enrollment

120

Registered

2023-09-16

Start date

2021-03-21

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vein thrombosis. Portal vein thrombosis

Interventions

Intervention 1: Intervention group: Flushing 2 cc of heparinized normal saline with a concentration of 2 units of heparin per cc every 8 hours after central venous catheter insertion. Intervention 2:

Eligibility

Sex/Gender

All

Age

1 Months to 18 Years

Inclusion criteria

Inclusion criteria: All patients with central venous catheter admitted to the intensive care unit None of the bleeding risk factors Informed consent of the patient's parent or guardian to participate in the study Age one month to 18 years

Exclusion criteria

Exclusion criteria: Risk factors of central venous catheter thrombosis Anti-coagulant or anti-platelet medication use in the past 5 days Major surgery in the last 24 hours Glomerular filtration rate less than 30 Thrombocytopenia (platelets less than 50 thousand) Kidney, heart and liver disorders Uncontrolled blood pressure Lumbar puncture in the last 24 hours

Design outcomes

Primary

Measure	Time frame
Thrombosis. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: ultrasound.;Sepsis. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: Patient symptoms based on systemic inflammatory response syndrome.;Heart rate. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: Arterial pulse taking.;Body Tempretute. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: Thermometer.;Respiration rate. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: observation.;Hemoglobin. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: ELISA Kit.	—

Measure

Time frame

Thrombosis. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: ultrasound.;Sepsis. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: Patient symptoms based on systemic inflammatory response syndrome.;Heart rate. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: Arterial pulse taking.;Body Tempretute. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: Thermometer.;Respiration rate. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: observation.;Hemoglobin. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: ELISA Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Mohebbi

Tehran University of Medical Sciences

dr.m.mhb@gmail.com+98 21 7756 8801

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026